Table 4.
The predictive value of PCDH8 methylation for the progression-free survival in non muscle invasive bladder cancer (n = 233)
| Variable |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| PCDH8 methylation (M vs. U) |
4.893 |
1.872-9.433 |
<0.0001 |
2.523 |
1.654-7.431 |
0.0036 |
| Age (>65 vs. ≦65) |
0.896 |
0.873-5.215 |
0.8614 |
|
|
|
| Sex (Male vs. Female) |
1.213 |
0.855-5.217 |
0.5461 |
|
|
|
| Number (Multiple vs. Single) |
1.322 |
0.729-8.537 |
0.4668 |
|
|
|
| Size (>3 cm vs. ≤3 cm) |
1.227 |
0.579-11.460 |
0.4962 |
|
|
|
| Grade (G3 vs. G1 / G2) |
3.679 |
1.463-7.754 |
0.0017 |
1.874 |
1.237-6.873 |
0.0233 |
| Stage (T1 vs. Ta) | 1.625 | 0.893-6.792 | 0.0614 | |||
HR: Hazard Ratio; M: Methylated; U: Unmethylated.